Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

BACKGROUND: The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R., Mardis, Elaine R., Gnant, Michael, Sestak, Ivana, Ellis, Matthew J., Perou, Charles M., Bernard, Philip S., Parker, Joel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546262/
https://www.ncbi.nlm.nih.gov/pubmed/26297356
http://dx.doi.org/10.1186/s12920-015-0129-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546262/
https://www.ncbi.nlm.nih.gov/pubmed/26297356
http://dx.doi.org/10.1186/s12920-015-0129-6

Ejemplares similares